Clinical trial
Implementation and Evaluation of Preemptive Pharmacogenomics Testing in an Aging Population
Name
2020-1103
Description
The primary goal of this study is to conduct pharmacogenomics testing (a type of DNA test) within an aging population and measure the impact of this test on medication selection, dosing, healthcare utilization, and costs of care.
Trial arms
Trial start
2023-03-28
Estimated PCD
2025-01-01
Trial end
2025-05-01
Treatment
Multigene pharmacogenomics test
This multigene pharmacogenomics test will report genetic variation for genes that have Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines.
Arms:
Pharmacogenomics Testing
Size
2000
Primary endpoint
Number of pharmacogenomic results returned in patients' health records
Date of blood draw to test results reported in medical record, up to 1 month
Eligibility criteria
Inclusion Criteria:
* Follows at a Geisinger 65 Forward clinic location
* Active prescriptions for 5 or more medications
Exclusion Criteria:
* Liver transplantation
* Allogenic hematopoetic stem cell transplantation
* Previously enrolled in the Electronic Medical Records and Genomics (eMERGE) pharmacogenomics cohort
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'SCREENING', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 2000, 'type': 'ESTIMATED'}}
Updated at
2024-04-26
1 organization
1 product
2 indications
Organization
Geisinger ClinicIndication
PolypharmacyIndication
Pharmacogenomic Testing